ADVERSE EFFECTS OF ESKETAMINE IN TREATMENT RESISTANT DEPRESSION: A COMPREHENSIVE LITERATURE REVIEW (2020-2025)
Abstract
Background: Esketamine nasal spray represents the first FDA approved treatment with a novel mechanism of action for treatment resistant depression (TRD) in decades. While its efficacy has been well established, a thorough understanding of the adverse effect profile remains essential for informed clinical decision making and optimal patient safety. We therefore undertook this systematic review to characterize the safety profile of esketamine in treatment resistant depression.
Aim: This review examines esketamine's adverse effect profile, focusing on common effects, cardiovascular safety, urological considerations, cognitive outcomes, abuse liability, special populations, and serious adverse events.
Materials and Methods: We performed a comprehensive literature search across multiple databases including PubMed, Cochrane Library, Web of Science, Embase, Google Scholar, and MEDLINE for studies published 2020-2025.
Results: Common adverse effects like dissociation and sedation resolved within two hours. Blood pressure elevations normalized within 1.5 hours without intervention. Pre approval concerns were not confirmed: no bladder cystitis occurred despite years of exposure, cognitive function remained stable or improved, and misuse was rare (less than 0.01%). Serious adverse events were infrequent (less than 0.2% of sessions), occurring mainly during initial treatments. Mortality rates matched background rates in treatment resistant depression. Elderly patients showed similar tolerability but needed closer cardiovascular monitoring.
Conclusion: Under proper clinical supervision, esketamine shows an acceptable safety profile. Most adverse effects are temporary and mild to moderate. Long term studies extending up to 6.5 years found no evidence of organ damage, cognitive decline, or meaningful abuse problems. For patients who have failed multiple treatments, esketamine provides an important alternative with manageable safety concerns.
References
World Health Organization. (2023). Depressive disorder (depression) [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/depression
Kryst, J., Kawalec, P., & Pilc, A. (2020). Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy, 21(1), 9-20. https://doi.org/10.1080/14656566.2019.1683161
Janik, A., Qiu, X., Lane, R., Popova, V., Drevets, W. C., Canuso, C. M., Fu, D. J., Macaluso, M., Mattingly, G. W., Shelton, R. C., & Zajecka, J. M. (2025). Esketamine monotherapy in adults with treatment resistant depression: A randomized clinical trial. JAMA Psychiatry, 82(9), 877-887. https://doi.org/10.1001/jamapsychiatry.2025.1317
Johnson & Johnson. (2025, January 21). SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment resistant depression. https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
Kalsi, S. S., Wood, D. M., & Dargan, P. I. (2011). The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal, 4, 7107. https://pubmed.ncbi.nlm.nih.gov/24149025/
Doherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A. (2020). Cardiac safety of esketamine nasal spray in treatment resistant depression: Results from the clinical development program. CNS Drugs, 34(3), 299-310. https://doi.org/10.1007/s40263-020-00699-4
Chu, P. S., Ma, W. K., Wong, S. C., Chu, R. W., Cheng, C. H., Wong, S., Tse, J. M., Lau, F. L., Yiu, M. K., & Man, C. W. (2008). The destruction of the lower urinary tract by ketamine abuse: A new syndrome? BJU International, 102(11), 1616-1622. https://doi.org/ 10.1111/j.1464-410X.2008.07920.x
Jhang, J. F., Hsu, Y. H., & Kuo, H. C. (2015). Possible pathophysiology of ketamine related cystitis and associated treatment strategies. International Journal of Urology, 22(9), 816-825. https://doi.org/10.1111/iju.12841
Morgan, C. J., Muetzelfeldt, L., & Curran, H. V. (2010). Consequences of chronic ketamine self administration upon neurocognitive function and psychological wellbeing: a 1 year longitudinal study. Addiction, 105(1), 121-133. https://doi.org/10.1111/j.1360-0443.2009.02761.x
Zaki, N., Chen, L. N., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Young, A. H., Lacerda, A. L. T., Paik, J. W., Popova, V., & Fu, D. J. (2025). Safety and efficacy with esketamine in treatment resistant depression: Long term extension study. International Journal of Neuropsychopharmacology, 28(6), pyaf027. https://doi.org/10.1093/ijnp/pyaf027
Sanacora, G., Heimer, R., Wang, J., Mathew, S. J., Gohar, S. M., Ahmed, M., Brown, B., Cabrera, P., Doherty, T., Himedan, M., Kern, D. M., Lim, L., Olsen-DeJong, C., Parker, N., Popova, V., Singh, J. B., Williamson, D., & Nemeroff, C. B. (2025). Real world safety of esketamine nasal spray: A comprehensive analysis almost 5 years after first approval. American Journal of Psychiatry. Advance online publication. https://doi.org/10.1176/appi.ajp.20240655
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., Ravindran, A., Gaillard, R., Van den Eynde, F., Ameele, H., Preskorn, S., Manji, H., Hough, D., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of fixed dose esketamine nasal spray combined with a new oral antidepressant in treatment resistant depression: Results of a randomized, double blind, active controlled study (TRANSFORM-1). International Journal of Neuropsychopharmacology, 22(10), 616-630. https://doi.org/10.1093/ijnp/pyz039
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment resistant depression: A randomized double blind active controlled study. American Journal of Psychiatry, 176(6), 428-438. https://doi.org/10.1176/appi.ajp.2019.19020172
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J., Silverman, B., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Manji, H., Drevets, W. C., & Singh, J. B. (2020). Esketamine nasal spray plus oral antidepressant in patients with treatment resistant depression: Assessment of long term safety in a phase 3, open label study (SUSTAIN-2). Journal of Clinical Psychiatry, 81(3), 19m12891. https://doi.org/10.4088/ JCP.19m12891
U.S. Food and Drug Administration. (2025). SPRAVATO® (esketamine) nasal spray, CIII [Prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., Thase, M. E., Zajecka, J., Winokur, A., Divacka, I., Fagiolini, A., Cubala, W. J., Bitter, I., Blier, P., Shelton, R. C.,... Singh, J. B. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment resistant depression: A randomized clinical trial. JAMA Psychiatry, 76(9), 893-903. https://doi.org/10.1001/jamapsychiatry.2019.1189
Findeis, H., Sauer, C., Cleare, A., Bauer, M., & Ritter, P. (2020). Urothelial toxicity of esketamine in the treatment of depression. Pharmacopsychiatry, 53(6), 266-270. https://doi.org/10.1055/a-1205-4923
Gałecki, P., & Bliźniewska-Kowalska, K. (2021). Treatment resistant depression: Recommendations of the National Consultant in the field of psychiatry. Psychiatria Polska, 55(6), 1443-1464. https://doi.org/10.12740/PP/115208
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021). Post marketing safety concerns with esketamine: A disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychotherapy and Psychosomatics, 90(1), 41-48. https://doi.org/10.1159/000510703
Orsolini, L., Salvi, V., & Volpe, U. (2022). Craving and addictive potential of esketamine as side effects? Expert Opinion on Drug Safety, 21(6), 803-812. https://doi.org/10.1080/14740338.2022.2047933
Chepke, C., Shelton, R., Sanacora, G., Doherty, T., Tsytsik, P., & Parker, N. (2024). Real world safety of esketamine nasal spray: A comprehensive analysis of esketamine and respiratory depression. International Journal of Neuropsychopharmacology, 27(12), pyae058. https://doi.org/10.1093/ijnp/pyae058
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., Steffens, D. C., Adler, C. M., McShane, R., Gaillard, R., Wilkinson, S. T., & Singh, J. B. (2020). Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment resistant depression: TRANSFORM-3. American Journal of Geriatric Psychiatry, 28(2), 121-141. https://doi.org/10.1016/j.jagp.2019.10.008
Morrison, R. L., et al. (2024). Effect of esketamine nasal spray on cognition in patients with treatment resistant depression: Results from four phase 3 studies. International Journal of Neuropsychopharmacology, 27(11), pyae046. https://doi.org/10.1093/ijnp/pyae046
Araújo, D., et al. (2024). Long term cognitive outcomes of esketamine nasal spray in treatment resistant depression: A preliminary report. Journal of Psychiatric Research, 171, 218-226. https://pmc.ncbi.nlm.nih.gov/articles/PMC11858642/
Ferreira-Santos, D., et al. (2021). The cognitive effects of esketamine: What do we know so far? European Psychiatry, 64(S1), S485. https://pmc.ncbi.nlm.nih.gov/articles/ PMC9567705/
Lan, H., et al. (2024). Effects of subanesthetic repeated esketamine infusions on memory function and NGF in patients with depression: An open label study. Journal of Affective Disorders, 367, 234-241. https://pmc.ncbi.nlm.nih.gov/articles/PMC9567705/
Canuso, C. M., et al. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide. American Journal of Psychiatry, 175(7), 620-630. https://pubmed.ncbi.nlm.nih.gov/29656663/
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998). Measurement of dissociative states with the Clinician Administered Dissociative States Scale (CADSS). Journal of Traumatic Stress, 11(1), 125-136. https://doi.org/10.1023/A:1024465317902
Views:
18
Downloads:
8
Copyright (c) 2026 Aleksandra Lejman, Rafał Bednarczyk, Natalia Bednarczyk, Radosław Krzysztof Binkowski, Agnieszka Kurek, Natalia Krajewska, Aleksandra Mazurkiewicz, Hubert Sidor, Monika Wołosik
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
